



Summit Corporation plc
(“Summit plc” or “the Company”)

APPOINTMENT OF TONY WEIR AS CHIEF FINANCIAL OFFICER

Oxford, UK, 28 October 2008 – Summit Corporation plc (AIM: SUMM), a leading UK biotechnology company, is pleased to announce the appointment of Mr Tony Weir (age 48) as the new Chief Financial Officer and member of the Board of Directors of the Company with effect from 17 November 2008.

Mr Weir will join Summit plc from Vernalis plc (LSE: VER) where he held the position of Chief Financial Officer for almost ten years. During that time, he guided the company through a range of transactions, including M&A, licensing deals and raising of finance. He is a Fellow of the Institute of Chartered Accountants, holds a degree in Mathematics from the University of Oxford and is also a non-executive director of Biocompatibles International plc.

Barry Price, PhD, Chairman of Summit, commented: “On behalf of the Board I would like to welcome Tony to Summit. We are delighted to have attracted someone of his calibre who will bring considerable financial experience as well as a deep understanding of the UK biotechnology sector. These qualities will be of great importance for Summit in meeting the future challenges we face in continuing to build a successful business.”

There is no further information required to be disclosed in accordance with Schedule 2, paragraph (g) of the AIM Rules for Companies.

- ENDS -

For more information, please contact:

Summit plc

Steven Lee, PhD, Chief Executive Officer
Richard Pye, PhD, Investor Relations

Tel: +44 (0)1235 443951; +44 (0)7825 313476

Citigate Dewe Rogerson

Mark Swallow, PhD / David Dible / Emma Palmer Foster

Tel: +44 (0)207 638 9571

Panmure Gordon

Andrew Burnett / Rakesh Sharma (Corporate Finance)
Ashton Clanfield (Corporate Broking)

Tel: +44 (0)207 459 3600

About Summit plc

Summit plc is a leading UK biotechnology company with a broad preclinical and clinical pipeline, two world-leading technology platforms and an innovative business model that is expected to generate sustainable value for investors.

Summit is developing multiple drug programmes that target unmet medical needs from which it intends to generate value by out-licensing attractive late preclinical or early clinical stage programmes in return for upfront, milestone and royalty payments. Summit uses its scientific expertise to target orphan diseases, neuro-disorders and infectious diseases. Summit has signed a major licensing agreement with BioMarin in Duchenne muscular dystrophy and has co-development agreements with Evolva (infectious diseases), Orient Pharma (sialorrhoea) and the Lilly TB Drug Discovery Initiative (tuberculosis)

Underpinning Summit's drug pipeline are two innovative technology platforms: carbohydrate chemistry and zebrafish biology. These platforms support existing programmes and also will be the source of future programmes to replenish Summit's drug pipeline. These platform technologies also form the basis of the Company's profitable service business.

The company listed on the alternative investment market (AIM) of the London Stock Exchange in October 2004 - symbol: SUMM. Further information about the company is available at www.summitplc.com.